Autopsy report · NCT01240941

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

“Funding was not available”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Vanderbilt-Ingram Cancer Center

Sponsor type

University, hospital or other

Conditions

Metastatic Breast Cancer

Interventions

MK-2206; Exemestane; Goserelin

Participants

0

Trials that died the same way

• Targeting Leukotrienes in Kidney Disease
  “Funding not available” (95% match in meaning)
• Brain Sleep Deprivation MRI Effects (BEDTIME)
  “Funding was not obtained” (93% match in meaning)
• Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
  “funding became unavailable” (91% match in meaning)
• Effects of Steroid Tapering on Functional Capacity and Neurocognition
  “Funding not obtained” (91% match in meaning)
• Evaluation and Adverse Event Surveillance for Initial Implementation of ShangRing Circumcision in Mozambique
  “Funding no longer available” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.